Asunaprevir

阿舒瑞韦

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAsunaprevir
Drug Alias Name阿那匹韦asAsunaprevir (NS3 inhibitor) - BMSunaprevirumasunaprevirSunvepra +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsLiver CirrhosisHepatic InsufficiencyHepatitis C, Chronic +[4] 
Global Approved IndicationsHepatitis C
Approved Indications in ChinaHepatitis C
Original Approved Country/TerritoryJapan
Original Approved Date2014/07/04
Country/TerritoryCanadaUnited StatesSweden +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb (China) Investment Co LtdCatalent Pharma SolutionsBristol-Myers Squibb (Singapore) Pte Ltd +[4] 
Inactive CompaniesBristol Myers Squibb Srlcompany
Active IndicationsHepatitis C, ChronicHepatitis C
Inactive IndicationsLiver CirrhosisHepatic Insufficiency

Other Information

ATC CodeJ05AP06
Related LinksWikipediaKEGG